Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Lafayette

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Lancet (London, England)|August 17, 2023
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trialRichard Lafayette, Jens Kristensen, Andrew Stone, et al.
Kidney International|June 28, 2025
Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathyJürgen Floege, Richard Lafayette, Jonathan Barratt, et al.
Kidney International Reports|July 18, 2025
Erratum to "Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts" [<i>Kidney International Reports</i> Volume 10, Issue 4, April 2025, Pages 1283-1287]Sean J Barbour, Rosanna Coppo, Jonathan Barratt, et al.
Glomerular Diseases|February 8, 2023
The Development and Use of an EHR-Linked Database for Glomerular Disease Research and Quality InitiativesRichard N Eikstadt, Hailey E Desmond, Clare Lindner, et al.
Kidney International|March 29, 2024
A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathyRichard Lafayette, Sean Barbour, Rubeen Israni, et al.
Kidney International Reports|December 22, 2025
Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY TrialVlado Perkovic, Jonathan Barratt, Richard Lafayette, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 20, 2023
Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous NephropathySean J Barbour, Fernando C Fervenza, Dilshani Induruwage, et al.
Clinical Chemistry|October 9, 2024
Deconvolution of Human Urine across the Transcriptome and MetabolomeSevahn K Vorperian, Brian C DeFelice, Joseph A Buonomo, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Multiomics characterization of cell type repertoires for urine liquid biopsiesSevahn K Vorperian, Brian C DeFelice, Joseph A Buonomo, et al.
Glomerular Diseases|February 8, 2023
Association between Psychiatric Disorders and Glomerular DiseaseHailey E Desmond, Clare Lindner, Jonathan P Troost, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Lancet (London, England)|August 17, 2023
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trialRichard Lafayette, Jens Kristensen, Andrew Stone, et al.
Kidney International|June 28, 2025
Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathyJürgen Floege, Richard Lafayette, Jonathan Barratt, et al.
Kidney International Reports|July 18, 2025
Erratum to "Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts" [<i>Kidney International Reports</i> Volume 10, Issue 4, April 2025, Pages 1283-1287]Sean J Barbour, Rosanna Coppo, Jonathan Barratt, et al.
Glomerular Diseases|February 8, 2023
The Development and Use of an EHR-Linked Database for Glomerular Disease Research and Quality InitiativesRichard N Eikstadt, Hailey E Desmond, Clare Lindner, et al.
Kidney International|March 29, 2024
A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathyRichard Lafayette, Sean Barbour, Rubeen Israni, et al.
Kidney International Reports|December 22, 2025
Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY TrialVlado Perkovic, Jonathan Barratt, Richard Lafayette, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 20, 2023
Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous NephropathySean J Barbour, Fernando C Fervenza, Dilshani Induruwage, et al.
Clinical Chemistry|October 9, 2024
Deconvolution of Human Urine across the Transcriptome and MetabolomeSevahn K Vorperian, Brian C DeFelice, Joseph A Buonomo, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Multiomics characterization of cell type repertoires for urine liquid biopsiesSevahn K Vorperian, Brian C DeFelice, Joseph A Buonomo, et al.
Glomerular Diseases|February 8, 2023
Association between Psychiatric Disorders and Glomerular DiseaseHailey E Desmond, Clare Lindner, Jonathan P Troost, et al.
Pageof 5